Aclerastide
Based on 1 Customer Validation
Aclerastide (DSC-127) is an angiotensin receptor agonist. Aclerastide also is a peptide analog of angiotensin II. Aclerastide can be used for the research of tissue regeneration in diabetic ulcers.
For research use only. We do not sell to patients.
- Purity: 99.62%
- CAS No.: 227803-63-6
- Formula: C42H64N12O11
- Molecular Weight:913.03
-
Storage:
Sealed storage, away from moisture and light.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Clinical Compound Library
HY-L026
-
Drug Repurposing Compound Library
HY-L035
-
Anti-diabetic Compound Library
HY-L040
-
Neurotransmitter Receptor Compound Library
HY-L062
-
Angiogenesis-Related Compound Library
HY-L088
-
Peptide Library
HY-L105
-
Heterocyclic Compound Library
HY-L138
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Peptide Compound Library
HY-L105S
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
All Angiotensin Receptor Isoforms
More
Biological Activity
Aclerastide (topically administered; 100 μL; once a day; for 14 days) elevates levels of reactive oxygen species and of active MMP-9[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:db/db mice[2]
-
Dosage:100 μL
-
Administration:Topically administered, once a day, for 14 days
-
Result:Upregulated reactive oxygen species during inflammation.
Increased the levels of the detrimental active MMP-9 in diabetic wounds.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 227803-63-6
-
Appearance Solid
-
Molecular Weight 913.03
-
Formula C42H64N12O11
-
Color White to off-white
-
Synonyms
DSC-127; NorLeu3-A(1-7)
-
Sequence
Asp-Arg-{Nle}-Tyr-Ile-His-Pro
-
Sequence Shortening
DR-{Nle}-YIHP
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture and light
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
DMSO : ≥ 100 mg/mL (109.53 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kathleen E Rodgers, et al. Acceleration of healing, reduction of fibrotic scar, and normalization of tissue architecture by an angiotensin analogue, NorLeu3-A(1-7). Plast Reconstr Surg. 2003 Mar;111(3):1195-206. [Content Brief]
[2]. Trung T Nguyen, et al. Expression of active matrix metalloproteinase-9 as a likely contributor to the clinical failure of aclerastide in treatment of diabetic foot ulcers. Eur J Pharmacol. 2018 Sep 5;834:77-83. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.0953 mL | 5.4763 mL | 10.9525 mL | 27.3814 mL |
| 5 mM | 0.2191 mL | 1.0953 mL | 2.1905 mL | 5.4763 mL | |
| 10 mM | 0.1095 mL | 0.5476 mL | 1.0953 mL | 2.7381 mL | |
| 15 mM | 0.0730 mL | 0.3651 mL | 0.7302 mL | 1.8254 mL | |
| 20 mM | 0.0548 mL | 0.2738 mL | 0.5476 mL | 1.3691 mL | |
| 25 mM | 0.0438 mL | 0.2191 mL | 0.4381 mL | 1.0953 mL | |
| 30 mM | 0.0365 mL | 0.1825 mL | 0.3651 mL | 0.9127 mL | |
| 40 mM | 0.0274 mL | 0.1369 mL | 0.2738 mL | 0.6845 mL | |
| 50 mM | 0.0219 mL | 0.1095 mL | 0.2191 mL | 0.5476 mL | |
| 60 mM | 0.0183 mL | 0.0913 mL | 0.1825 mL | 0.4564 mL | |
| 80 mM | 0.0137 mL | 0.0685 mL | 0.1369 mL | 0.3423 mL | |
| 100 mM | 0.0110 mL | 0.0548 mL | 0.1095 mL | 0.2738 mL |
Powered by Bioz